MIM
XFOR icon

MetLife Investment Management’s X4 Pharmaceuticals XFOR Stock Holding History

MetLife Investment Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Buy
+47,969
New +$197K ﹤0.01% 2363
2023
Q4 		– Sell
-2,181
Closed -$71.3K – 2868
2023
Q3 		$71.3K Hold
2,181
– – ﹤0.01% 2753
2023
Q2 		$127K Buy
+2,181
New +$112K ﹤0.01% 2539

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MetLife Investment Management's XFOR Position: Q2 2026 in Review

MetLife Investment Management opened a new position in X4 Pharmaceuticals (XFOR) in Q2 2026: 47,969 shares worth $224K. The stake represents ﹤0.01% of the portfolio and ranks #2363 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in XFOR as recently as Q3 2023.

MetLife Investment Management first reported a position in XFOR in Q2 2023 and has held it in 3 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • MetLife Investment Management held 47,969 shares of X4 Pharmaceuticals worth $224K as of Q2 2026.
  • X4 Pharmaceuticals was a new MetLife Investment Management position in Q2 2026.
  • X4 Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2363 holding.
  • MetLife Investment Management first reported a position in X4 Pharmaceuticals in Q2 2023 and has held it in 3 quarters since.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.